Investors & Media

What’s new.

Press releases

Press releases.

June 27th 2024

Immutep Reports Positive Topline Results from TACTI-003 Phase IIb Trial in First Line Head and Neck Cancer

June 25th 2024

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

June 5th 2024

Immutep successfully completes institutional placement and institutional component of entitlement offer

more

Investor updates

Investor updates.

February 21st 2024

Investor Update - February 2024

August 18th 2023

Investor Update - August 2023

November 17th 2022

Investor Update - November 2022

more

Analyst reports

Analyst reports.

June 28th 2024

Bell Potter - Combo data supportive in HNSCC; Retain Buy, A$0.75 (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

June 28th 2024

Canaccord Genuity - Headstrong conviction in Efti's potential clinical impact; Maintain Buy, A$0.95 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

Wilsons - TACTI-003 download: take a pause; Maintain Overweight, A$1.13 PT (Analysts: Dr Melissa Benson and Dr Shane Storey)

more